Newron Pharmaceuticals — H125 results reflect evenamide progress
H125 saw Newron Pharmaceuticals make significant clinical headway with lead asset evenamide, culminating in the initiation of the first Phase III...
279 Views
Newron Pharmaceuticals — ENIGMA-TRS 1 commences enrolment
Newron Pharmaceuticals has confirmed that enrolment has begun for its registrational ENIGMA-TRS Phase III programme for lead candidate evenamide....
226 Views
Newron Pharmaceuticals — Evenamide enters ENIGMA-TRS programme
Newron Pharmaceuticals is making significant headway in progressing its drug candidate, evenamide, to become an effective treatment option for...
408 Views
Newron Pharmaceuticals — Next stage unlocked for evenamide
Newron has announced receipt of regulatory clearance to conduct its Phase III programme for evenamide (ENIGMA-TRS), taking it one step closer to...
310 Views
Newron Pharmaceuticals — Pivotal evenamide trial looms
Newron Pharmaceuticals has published its FY24 results, reflecting a rewarding period for its lead clinical candidate, evenamide, which is being...
362 Views